Recovery of Recurrent Laryngeal Nerve Function With Neoadjuvant Treatment: Neural Characterization.

neoadjuvant paralysis recovery recurrent laryngeal nerve surgery thyroid

Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
24 Jan 2024
Historique:
revised: 20 12 2023
received: 22 08 2023
accepted: 12 01 2024
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 24 1 2024
Statut: aheadofprint

Résumé

Neoadjuvant targeted therapy has emerged as a promising treatment strategy for locally aggressive thyroid cancer. Its impact on tumor and adjacent tissues remains a nascent area of study. Here we report on a series of six subjects with locally advanced thyroid cancer and recurrent laryngeal nerve (RLN) paralysis who experienced recovery of RLN function with neoadjuvant treatment and describe the morphologic and electrophysiologic characteristics of these recovered nerves. This is a multicenter retrospective review. Descriptive analysis was conducted to examine the following parameters for recovered nerves: (1) nerve morphology, characterized as Type A (involving epineurium only) versus Type B (extending beyond epineurium); (2) proximal stimulability (normal vs. abnormal vs. absent); and (3) surgical management (resection vs. preservation). Six subjects with unilateral VFP were identified. Median time to return of VF mobility was 3 months (range 2-13.5). All nerves (100%) were noted to have Type A morphology at surgery. Proximal stimulability was normal in four subjects (66.7%), abnormal in one (16.7%), and absent in one (16.7%). Nerves that had improvement of function through neoadjuvant therapy were able to be surgically preserved in five subjects (83.3%). This represents the first characterization of RLNs that have recovered function with neoadjuvant treatment of locally advanced thyroid cancer. Although much remains unknown, our findings indicate carcinomatous neural invasion is a reversible process and recovered nerves may demonstrate normal morphology and electrophysiologic activity. 4 Laryngoscope, 2024.

Identifiants

pubmed: 38264976
doi: 10.1002/lary.31304
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 The American Laryngological, Rhinological and Otological Society, Inc.

Références

Zhao X, Wang JR, Dadu R, et al. Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid. 2023;33:484-491.
Contrera KJ, Gule-Monroe M, Hu MI, et al. Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series. Thyroid. 2022;33:129-132.
McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck. 1994;16(2):165-172.
Kowalski LP, Filho JG. Results of the treatment of locally invasive thyroid carcinoma. Head Neck. 2002;24(4):340-344.
Nishida T, Nakao K, Hamaji M, Kamiike W, Kurozumi K, Matsuda H. Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer. Ann Surg. 1997;226(1):85-91.
Karcioglu AS, Abdelhamid Ahmed AH, Feng Z, et al. Return of vocal fold motion and surgical preservation of invaded recurrent laryngeal nerves after the use of Neoadjuvant therapy in patients presenting with advanced thyroid cancer and vocal fold paralysis: the Lazarus effect. Thyroid. 2023;33(10):1259-1263.
Brooks JA, Abdelhamid Ahmed AH, Al-Qurayshi Z, Kamani D. Recurrent laryngeal nerve invasion by thyroid cancer: laryngeal function and survival outcomes. Laryngoscope. 2022;132:2285-2292.
Wu CW, Dionigi G, Barczynski M, et al. International neuromonitoring study group guidelines 2018: part II: optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data. Laryngoscope. 2018;128(Suppl 3):S18-S27.
Kamani D, Darr EA, Randolph GW. Electrophysiologic monitoring characteristics of the recurrent laryngeal nerve preoperatively paralyzed or invaded with malignancy. Otolaryngol Head Neck Surg. 2013;149(5):682-688.
Mu L, Yang S. An experimental study on the laryngeal electromyography and visual observations in varying types of surgical injuries to the unilateral recurrent laryngeal nerve in the neck. Laryngoscope. 1991;101(7 Pt 1):699-708.
Chi SY, Lammers B, Boehner H, Pohl P, Goretzki PE. Is it meaningful to preserve a palsied recurrent laryngeal nerve? Thyroid. 2008;18(3):363-366.
Randolph GW, Kamani D. The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy. Surgery. 2006;139(3):357-362.
Farrag TY, Samlan RA, Lin FR, Tufano RP. The utility of evaluating true vocal fold motion before thyroid surgery. Laryngoscope. 2006;116(2):235-238.
Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2013;31(3):379-385.
A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer [Internet]. Report No.: NCT04321954. 2022. Accessed April 2, 2023. https://clinicaltrials.gov/ct2/show/NCT04321954.

Auteurs

Marika D Russell (MD)

Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.

Amr H Abdelhamid Ahmed (AH)

Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.

Zipei Feng (Z)

Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A.

David C Shonka (DC)

Department of Otolaryngology-Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia, U.S.A.

Amanda S Karcioglu (AS)

Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.
Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, NorthShore University HealthSystem, Evanston, Illinois, U.S.A.
The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, U.S.A.

Ayaka J Iwata (AJ)

Department of Otolaryngology-Head and Neck Surgery, Kaiser Permanente Santa Clara Medical Center, Santa Clara, California, U.S.A.

Natalia Kyriazidis (N)

Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.

Sameer H Siddiqui (SH)

McGovern Medical School at University of Texas Health Science Center, Houston, Texas, U.S.A.

Tejas S Athni (TS)

Harvard Medical School, Boston, Massachusetts, U.S.A.

Jong C Park (JC)

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.

Lori J Wirth (LJ)

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.

Mark E Zafereo (ME)

Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A.

Gregory W Randolph (GW)

Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.

Classifications MeSH